Founded on groundbreaking immuno-neurology research by Tranquis’ scientific founder, Dr. Edgar Engleman, and his team at Stanford, we are discovering and developing a novel portfolio of small molecule therapeutic candidates which cross the blood-brain barrier to target the underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. Our ambition is to revolutionize the management ...
Founded on groundbreaking immuno-neurology research by Tranquis’ scientific founder, Dr. Edgar Engleman, and his team at Stanford, we are discovering and developing a novel portfolio of small molecule therapeutic candidates which cross the blood-brain barrier to target the underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. Our ambition is to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.